The clinical treatment of chronic obstructive pulmonary disease (COPD) requires not only an improvement of airflow by bronchodilation but also the suppression of emphysema by controlling inflammation. Here we screen a compound library consisting of clinically used drugs for their ability to prevent elastase-induced airspace enlargement in mice. We show that intratracheal administration or inhalation of mepenzolate bromide, a muscarinic antagonist used to treat gastrointestinal disorders, decreases the severity of elastase-induced airspace enlargement and respiratory dysfunction. Although mepenzolate bromide shows bronchodilatory activity, most other muscarinic antagonists do not improve elastase-induced pulmonary disorders. Apart from suppressing elastase-induced pulmonary inflammatory responses and the production of superoxide anions, mepenzolate bromide reduces the level of cigarette smoke-induced airspace enlargement and respiratory dysfunction. Based on these results, we propose that mepenzolate bromide may be an effective therapeutic for the treatment of COPD due to its anti-inflammatory and bronchodilatory activities.
In
situ click chemistry has great potential for identifying enzyme
inhibitors. However, conventional in situ click chemistry provides
extremely low yields of the products, making it incompatible with
direct activity-based assays. Here, to address this issue, we focused
on the catalysis of azide–alkyne cycloaddition (AAC) by the
metal ion in metalloproteins. We chose 2-ethynyl N-heterocompounds as alkyne fragments which are activated by coordination
to the metal ion. For proof of concept, we applied metal ion-catalyzed
in situ AAC to identify inhibitors of Fe(II)-dependent lysine demethylase
5C (KDM5C). The triazole product was obtained in dramatically high
yield, dependently on Fe(II) in KDM5C, and the metalloprotein-catalyzed
click reaction was compatible with activity-based high-throughput
screening, enabling us to discover a potent KDM5C inhibitor. Thus,
metal-catalyzed in situ AAC should be generally applicable to other
metalloproteins.
We developed a first-in-class proteolysis targeting chimera (PROTAC) for selective degradation of histone deacetylase 8 (HDAC8). The PROTAC induced degradation of HDAC8 without affecting the levels of other HDACs in...
Fat
mass obesity-associated protein (FTO) is a DNA/RNA demethylase
involved in the epigenetic regulation of various genes and is considered
a therapeutic target for obesity, cancer, and neurological disorders.
Here, we aimed to design novel FTO-selective inhibitors by merging
fragments of previously reported FTO inhibitors. Among the synthesized
analogues, compound 11b, which merges key fragments of
Hz (3) and MA (4), inhibited FTO selectively
over alkylation repair homologue 5 (ALKBH5), another DNA/RNA demethylase.
Treatment of acute monocytic leukemia NOMO-1 cells with a prodrug
of 11b decreased the viability of acute monocytic leukemia
cells, increased the level of the FTO substrate N
6-methyladenosine in mRNA, and induced upregulation of MYC and downregulation of RARA, which are
FTO target genes. Thus, Hz (3)/MA (4) hybrid
analogues represent an entry into a new class of FTO-selective inhibitors.
Reaction conditions have been identified to conduct a one-pot asymmetric organocatalytic aldol reaction with a hydrophobic substrate in aqueous medium via a process running in flow mode. By employing a mixture of water and 2-propanol, a hydrophobic aldehyde and 3.6 mol% of an organocatalyst, this microreactor process affords the desired aldol adduct with a conversion of 74% and an enantioselectivity of 89% after a reaction time of 60 minutes.
Non-steroidal anti-inflammatory drugs (NSAIDs) achieve their anti-inflammatory effect by inhibiting cyclooxygenase activity. We previously suggested that in addition to cyclooxygenase-inhibition at the gastric mucosa, NSAID-induced gastric mucosal cell death is required for the formation of NSAID-induced gastric lesions in vivo. We showed that celecoxib exhibited the most potent membrane permeabilizing activity among the NSAIDs tested. In contrast, we have found that the NSAID rofecoxib has very weak membrane permeabilizing activity. To understand the membrane permeabilizing activity of coxibs in terms of their structure-activity relationship, we separated the structures of celecoxib and rofecoxib into three parts, synthesized hybrid compounds by substitution of each of the parts, and examined the membrane permeabilizing activities of these hybrids. The results suggest that the sulfonamidophenyl subgroup of celecoxib or the methanesulfonylphenyl subgroup of rofecoxib is important for their potent or weak membrane permeabilizing activity, respectively. These findings provide important information for design and synthesis of new coxibs with lower membrane permeabilizing activity.
We used protein−compound docking simulations to develop a structure‐based quantitative structure−activity relationship (QSAR) model. The prediction model used docking scores as descriptors. The binding free energy was approximated by a weighted average of docking scores for multiple proteins. This approximation was based on a pharmacophore model of receptor pockets and compounds. The weights of the docking scores were restricted to small values to avoid unrealistic weights by a regularization term. Additional outlier elimination improved the results. We applied this method to two groups of targets. The first target was the kinase family. The cross‐validation results of 107 kinase proteins showed that the RMSE of predicted binding free energies was 1.1 kcal/mol. The second target was the matrix metalloproteinase (MMP) family, which has been difficult for docking programs. MMPs require metal‐binding groups in their inhibitor structures in many cases. A quantum effect contributes to the metal−ligand interaction. Despite this difficulty, the present method worked well for the MMPs. This method showed that the RMSE of predicted binding free energies was 1.1 kcal/mol. In comparison, with the original docking method the RMSE was 1.7 kcal/mol. The results suggest that the present QSAR model should be applied to general target proteins.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.